Cue Biopharma granted equity awards to seven new employees, including CEO Shao-Lee Lin, as part of its inducement plan.
Quiver AI Summary
Cue Biopharma, Inc. announced the granting of inducement equity awards to seven new employees, including its new president and CEO, Dr. Shao-Lee Lin, on May 3, 2026. These awards, approved by the company's independent directors, were made under the 2026 Inducement Stock Incentive Plan in line with Nasdaq regulations. Dr. Lin received a stock option for 655,074 shares and restricted stock units for 327,537 shares, with the option vesting over four years and the RSU fully vested upon grant. The other six new employees received options for 518,599 shares and RSUs for 327,534 shares, with similar vesting terms. Cue Biopharma focuses on developing innovative therapies for immunological disorders, including a novel anti-IgE antibody currently in Phase 2 development and other candidates advancing towards clinical trials.
Potential Positives
- Appointment of Dr. Shao-Lee Lin as the new president and CEO, indicating a strategic leadership change that may bring new vision and direction to the company.
- Granting significant equity awards to new employees, demonstrating the company's commitment to attracting and retaining talent in key positions.
- The issuance of inducement equity awards aligns with Nasdaq regulations, enhancing corporate governance standards and transparency.
- Cue Biopharma is advancing its clinical pipeline with promising therapies, including a dual-mechanism anti-IgE antibody and the Immuno-STAT® platform, indicating potential growth and future revenue opportunities.
Potential Negatives
- High equity awards for new executives could raise concerns among investors about potential overcompensation and misalignment with company performance, especially in a clinical stage company.
- The decision to grant fully vested restricted stock units upon hire may lead to adverse perceptions regarding the retention strategy and commitment of new hires to the company’s long-term success.
- Reliance on inducement equity grants could suggest challenges in attracting talent without significant financial incentives, which may indicate underlying issues with the company’s employment appeal or workplace culture.
FAQ
What equity awards did Cue Biopharma grant recently?
Cue Biopharma granted inducement equity awards to seven new employees, including stock options and restricted stock units, on May 3, 2026.
Who is the new CEO of Cue Biopharma?
The new CEO of Cue Biopharma is Shao-Lee Lin, M.D., Ph.D., appointed on May 3, 2026.
What is the exercise price for the granted stock options?
The exercise price for the stock options granted is $30.42 per share, based on the closing price on May 1, 2026.
How are the stock options structured for the new employees?
The stock options for new employees will vest in equal quarterly installments over four years, subject to continued employment.
What is Cue Biopharma's focus as a company?
Cue Biopharma focuses on developing transformative therapies to enable functional cures for immunological disorders and has several clinical-stage assets.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CUE Insider Trading Activity
$CUE insiders have traded $CUE stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CUE stock by insiders over the last 6 months:
- PASHA SARRAF has made 5 purchases buying 323,857 shares for an estimated $99,747 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$CUE Hedge Fund Activity
We have seen 14 institutional investors add shares of $CUE stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LION POINT CAPITAL, LP added 2,202,854 shares (+inf%) to their portfolio in Q4 2025, for an estimated $672,751
- GC WEALTH MANAGEMENT RIA, LLC added 1,200,000 shares (+35.0%) to their portfolio in Q4 2025, for an estimated $366,480
- ROBERTSON STEPHENS WEALTH MANAGEMENT, LLC removed 462,550 shares (-96.7%) from their portfolio in Q1 2026, for an estimated $3,190,207
- TEXAS CAPITAL BANK WEALTH MANAGEMENT SERVICES INC added 407,568 shares (+1231.2%) to their portfolio in Q4 2025, for an estimated $124,471
- ANGELES WEALTH MANAGEMENT, LLC removed 299,667 shares (-96.7%) from their portfolio in Q1 2026, for an estimated $2,066,803
- BANK OF AMERICA CORP /DE/ removed 116,952 shares (-36.0%) from their portfolio in Q4 2025, for an estimated $35,717
- BOOTHBAY FUND MANAGEMENT, LLC added 93,333 shares (+15.3%) to their portfolio in Q4 2025, for an estimated $28,503
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Full Release
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief executive officer, Shao-Lee Lin, M.D., Ph.D. The equity awards were made pursuant to the Company’s 2026 Inducement Stock Incentive Plan and were unanimously approved by the independent directors of the Company as an inducement material to each new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants made to Dr. Lin consisted of (i) a non-statutory stock option to purchase 655,074 shares of common stock, at an exercise price of $30.42 per share, which was the closing price of a share of the Company’s common stock on the Nasdaq Capital Market on May 1, 2026, and (ii) restricted stock units with respect to 327,537 shares of common stock. Dr. Lin’s option will vest in equal, monthly installments over four years from her start date, subject to continued employment with the Company through each applicable vesting date. Dr. Lin’s restricted stock unit award was fully vested upon grant.
The inducement grants made to the six other new employees consisted of (i) non-statutory stock options to purchase an aggregate of 518,599 shares of common stock, at an exercise price of $30.42 per share, which was the closing price of a share of the Company’s common stock on the Nasdaq Capital Market on May 1, 2026, and (ii) restricted stock unit awards with respect to an aggregate of 327,534 shares of common stock. The option grants will vest in equal, quarterly installments over four years from each employee’s start date, subject to each employee’s continued employment with the Company through each applicable vesting date. The restricted stock unit awards were fully vested upon grant.
About Cue Biopharma
Cue Biopharma (Nasdaq: CUE) is a clinical stage therapeutics company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT
®
platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.
Investor and Media Contact
[email protected]
Cue Biopharma, Inc.
